Boston Scientific is trading at $45.82 (-4.14%) after withdrawing its third-quarter and full-year 2026 sales and adjusted-profit forecasts following an August 25 cybersecurity incident.
- The incident disrupted manufacturing, order processing, and global shipments; Reuters reported the company expects a material impact on results.
- Boston Scientific said product function was not impaired, while remote-monitoring activations were restored.
- Shares were down 4.5% in premarket trading as the incident outweighed broader healthcare weakness and modestly lower U.S. equity markets.